Vemurafenib-induced autophagy was independent of MAPK signaling pathway and was mediated through the ER stress response. Finally, administration of vemurafenib with the autophagy inhibitor hydroxychloroquine promoted more pronounced tumor suppression in vivo. Conclusions: Our data demonstrate that vemurafenib induces ER stress response–mediated autophagy in thyroid cancer and autophagy inhibition may be a beneficial strategy to sensitize BRAF-mutant thyroid cancer to vemurafenib. Wang, Weibin Kang, Helen Zhao, Yinu Min, Irene Wyrwas, Brian Moore, Maureen Teng, Lisong Zarnegar, Rasa Jiang, Xuejun Fahey, Thomas J Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. The RAF inhibitor vemurafenib has provided a major advance for the treatment of patients with BRAF-mutant metastatic melanoma. However, BRAF-mutant thyroid cancer is relatively resistant to vemurafenib, and the reason for this disparity remains unclear. Anticancer therapy-induced autophagy can trigger adaptive drug resistance in a variety of cancer types and treatments.
0 kommentar(er)
